| Vaccination | Natural Exposure | Total |
---|---|---|---|
Geographic location of study population | |||
Asia | 2 | 15 | 17 |
North America | 5 | 11 | 15* |
South America | 0 | 1 | 1 |
Africa | 0 | 0 | 0 |
Australia | 1 | 0 | 1 |
Europe | 0 | 2 | 2 |
Not reported | 1 | 1 | 1* |
Neutralization percentage | |||
50 % | 5 | 18 | 23 |
70 % | 0 | 3 | 3 |
80 % | 2 | 2 | 3* |
90 % | 0 | 1 | 1 |
Not reported | 1 | 2 | 3 |
Cell line | |||
BHK | 0 | 9 | 9 |
LLC-MK2 | 5 | 11 | 16 |
Vero | 3 | 4 | 6* |
Not reported | 0 | 2 | 2 |
Virus concentration (plaque-forming units [pfu] or focus-forming units [ffu] per microliter [uL] or milliliter [mL]) | |||
10-20 pfu / 10 uL | 0 | 1 | 1 |
10-20 pfu / 50 uL | 0 | 2 | 2 |
15-25 pfu / 25 uL | 0 | 2 | 2 |
20-30 pfu / 12.5 uL | 0 | 2 | 2 |
40-80 pfu / 100 uL | 0 | 1 | 1 |
50 pfu / 150 uL | 3 | 4 | 7 |
107 pfu / mL | 2 | 0 | 2 |
25-50 pfu | 0 | 1 | 1 |
50 pfu | 0 | 1 | 1 |
320 pfu | 0 | 1 | 1 |
100 ffu / 90 uL | 0 | 1 | 1 |
800 ffu | 1 | 1 | 1* |
Not reported | 2 | 8 | 10 |